Structural differences determine the relative selectivity of nicotinic compounds for native alpha 4 beta 2*-, alpha 6 beta 2*-, alpha 3 beta 4*- and alpha 7-nicotine acetylcholine receptors. 2010

Sharon R Grady, and Ryan M Drenan, and Scott R Breining, and Daniel Yohannes, and Charles R Wageman, and Nikolai B Fedorov, and Sheri McKinney, and Paul Whiteaker, and Merouane Bencherif, and Henry A Lester, and Michael J Marks
Institute for Behavioral Genetics, University of Colorado, Boulder, CO 80309, USA. sharon.grady@colorado.edu

Mammalian brain expresses multiple nicotinic acetylcholine receptor (nAChR) subtypes that differ in subunit composition, sites of expression and pharmacological and functional properties. Among known subtypes of receptors, alpha 4 beta 2* and alpha 6 beta 2*-nAChR have the highest affinity for nicotine (where * indicates possibility of other subunits). The alpha 4 beta 2*-nAChRs are widely distributed, while alpha 6 beta 2*-nAChR are restricted to a few regions. Both subtypes modulate release of dopamine from the dopaminergic neurons of the mesoaccumbens pathway thought to be essential for reward and addiction. alpha 4 beta 2*-nAChR also modulate GABA release in these areas. Identification of selective compounds would facilitate study of nAChR subtypes. An improved understanding of the role of nAChR subtypes may help in developing more effective smoking cessation aids with fewer side effects than current therapeutics. We have screened a series of nicotinic compounds that vary in the distance between the pyridine and the cationic center, in steric bulk, and in flexibility of the molecule. These compounds were screened using membrane binding and synaptosomal function assays, or recordings from GH4C1 cells expressing h alpha 7, to determine affinity, potency and efficacy at four subtypes of nAChRs found in brain, alpha 4 beta 2*, alpha 6 beta 2*, alpha 7 and alpha 3 beta 4*. In addition, physiological assays in gain-of-function mutant mice were used to assess in vivo activity at alpha 4 beta 2* and alpha 6 beta 2*-nAChRs. This approach has identified several compounds with agonist or partial agonist activity that display improved selectivity for alpha 6 beta 2*-nAChR.

UI MeSH Term Description Entries
D008822 Mice, Transgenic Laboratory mice that have been produced from a genetically manipulated EGG or EMBRYO, MAMMALIAN. Transgenic Mice,Founder Mice, Transgenic,Mouse, Founder, Transgenic,Mouse, Transgenic,Mice, Transgenic Founder,Transgenic Founder Mice,Transgenic Mouse
D011487 Protein Conformation The characteristic 3-dimensional shape of a protein, including the secondary, supersecondary (motifs), tertiary (domains) and quaternary structure of the peptide chain. PROTEIN STRUCTURE, QUATERNARY describes the conformation assumed by multimeric proteins (aggregates of more than one polypeptide chain). Conformation, Protein,Conformations, Protein,Protein Conformations
D011725 Pyridines Compounds with a six membered aromatic ring containing NITROGEN. The saturated version is PIPERIDINES.
D011978 Receptors, Nicotinic One of the two major classes of cholinergic receptors. Nicotinic receptors were originally distinguished by their preference for NICOTINE over MUSCARINE. They are generally divided into muscle-type and neuronal-type (previously ganglionic) based on pharmacology, and subunit composition of the receptors. Nicotinic Acetylcholine Receptors,Nicotinic Receptors,Nicotinic Acetylcholine Receptor,Nicotinic Receptor,Acetylcholine Receptor, Nicotinic,Acetylcholine Receptors, Nicotinic,Receptor, Nicotinic,Receptor, Nicotinic Acetylcholine,Receptors, Nicotinic Acetylcholine
D001831 Body Temperature The measure of the level of heat of a human or animal. Organ Temperature,Body Temperatures,Organ Temperatures,Temperature, Body,Temperature, Organ,Temperatures, Body,Temperatures, Organ
D001921 Brain The part of CENTRAL NERVOUS SYSTEM that is contained within the skull (CRANIUM). Arising from the NEURAL TUBE, the embryonic brain is comprised of three major parts including PROSENCEPHALON (the forebrain); MESENCEPHALON (the midbrain); and RHOMBENCEPHALON (the hindbrain). The developed brain consists of CEREBRUM; CEREBELLUM; and other structures in the BRAIN STEM. Encephalon
D002460 Cell Line Established cell cultures that have the potential to propagate indefinitely. Cell Lines,Line, Cell,Lines, Cell
D004353 Drug Evaluation, Preclinical Preclinical testing of drugs in experimental animals or in vitro for their biological and toxic effects and potential clinical applications. Drug Screening,Evaluation Studies, Drug, Pre-Clinical,Drug Evaluation Studies, Preclinical,Drug Evaluations, Preclinical,Evaluation Studies, Drug, Preclinical,Evaluation, Preclinical Drug,Evaluations, Preclinical Drug,Medicinal Plants Testing, Preclinical,Preclinical Drug Evaluation,Preclinical Drug Evaluations,Drug Screenings,Screening, Drug,Screenings, Drug
D004548 Elasticity Resistance and recovery from distortion of shape.
D000818 Animals Unicellular or multicellular, heterotrophic organisms, that have sensation and the power of voluntary movement. Under the older five kingdom paradigm, Animalia was one of the kingdoms. Under the modern three domain model, Animalia represents one of the many groups in the domain EUKARYOTA. Animal,Metazoa,Animalia

Related Publications

Sharon R Grady, and Ryan M Drenan, and Scott R Breining, and Daniel Yohannes, and Charles R Wageman, and Nikolai B Fedorov, and Sheri McKinney, and Paul Whiteaker, and Merouane Bencherif, and Henry A Lester, and Michael J Marks
May 2005, The Journal of biological chemistry,
Sharon R Grady, and Ryan M Drenan, and Scott R Breining, and Daniel Yohannes, and Charles R Wageman, and Nikolai B Fedorov, and Sheri McKinney, and Paul Whiteaker, and Merouane Bencherif, and Henry A Lester, and Michael J Marks
January 1997, The Journal of pharmacology and experimental therapeutics,
Sharon R Grady, and Ryan M Drenan, and Scott R Breining, and Daniel Yohannes, and Charles R Wageman, and Nikolai B Fedorov, and Sheri McKinney, and Paul Whiteaker, and Merouane Bencherif, and Henry A Lester, and Michael J Marks
January 1996, Journal of molecular neuroscience : MN,
Sharon R Grady, and Ryan M Drenan, and Scott R Breining, and Daniel Yohannes, and Charles R Wageman, and Nikolai B Fedorov, and Sheri McKinney, and Paul Whiteaker, and Merouane Bencherif, and Henry A Lester, and Michael J Marks
February 2003, Bioorganic & medicinal chemistry letters,
Sharon R Grady, and Ryan M Drenan, and Scott R Breining, and Daniel Yohannes, and Charles R Wageman, and Nikolai B Fedorov, and Sheri McKinney, and Paul Whiteaker, and Merouane Bencherif, and Henry A Lester, and Michael J Marks
July 2006, The Journal of pharmacology and experimental therapeutics,
Sharon R Grady, and Ryan M Drenan, and Scott R Breining, and Daniel Yohannes, and Charles R Wageman, and Nikolai B Fedorov, and Sheri McKinney, and Paul Whiteaker, and Merouane Bencherif, and Henry A Lester, and Michael J Marks
August 2006, Archives of general psychiatry,
Sharon R Grady, and Ryan M Drenan, and Scott R Breining, and Daniel Yohannes, and Charles R Wageman, and Nikolai B Fedorov, and Sheri McKinney, and Paul Whiteaker, and Merouane Bencherif, and Henry A Lester, and Michael J Marks
December 2003, Alcoholism, clinical and experimental research,
Sharon R Grady, and Ryan M Drenan, and Scott R Breining, and Daniel Yohannes, and Charles R Wageman, and Nikolai B Fedorov, and Sheri McKinney, and Paul Whiteaker, and Merouane Bencherif, and Henry A Lester, and Michael J Marks
January 2002, Neuroscience,
Sharon R Grady, and Ryan M Drenan, and Scott R Breining, and Daniel Yohannes, and Charles R Wageman, and Nikolai B Fedorov, and Sheri McKinney, and Paul Whiteaker, and Merouane Bencherif, and Henry A Lester, and Michael J Marks
April 1997, Anesthesiology,
Sharon R Grady, and Ryan M Drenan, and Scott R Breining, and Daniel Yohannes, and Charles R Wageman, and Nikolai B Fedorov, and Sheri McKinney, and Paul Whiteaker, and Merouane Bencherif, and Henry A Lester, and Michael J Marks
February 1996, Journal of neurochemistry,
Copied contents to your clipboard!